Payer Evidence Demands

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning. The payer evidence landscape is shifting in fascinating ways.

MarcusSame here. We're looking at how payer evidence requirements are evolving — that's reshaping entire HEOR strategies. Then the integration challenges for real-world evidence in submissions. Next, value demonstration for complex therapies. And finally, rare disease HTA methodological shifts.

SaraThat second one hits close to home — the RWE integration gap between what payers want and what HEOR can deliver is widening. The operational hurdles are significant.

MarcusExactly. Let's get into it.

MarcusLet's start with payer evidence requirements evolution. We're seeing a fundamental shift from traditional clinical endpoints to more holistic value assessments. Payers are demanding earlier evidence generation, often during Phase II, to inform coverage decisions. This requires HEOR teams to embed economic models and patient-reported outcomes much earlier in development.

SaraThat's one read — I'd frame it slightly differently. Payers aren't just asking for earlier data; they're demanding contextualization within real-world healthcare systems. The question isn't just 'does it work?' but 'how does it work within our existing resource constraints?' That's why we're seeing more conditional reimbursement frameworks tied to real-world evidence generation.

MarcusThat connects to something I keep coming back to — the budget impact considerations. Payers are increasingly requiring transparent modeling of opportunity costs. It's not just about the drug's price but about displacing other services. The part that gives me pause is how this affects development timelines for breakthrough therapies.

SaraThe part that gives me pause is the operational burden. HEOR teams are now expected to generate robust evidence while maintaining commercial viability. That's a delicate balance. I wonder if that's the full picture though — we're also seeing payers experiment with value-based agreements, which could actually streamline evidence requirements if designed well.

MarcusThat's fair, though I think payers would see it differently. They view value-based contracts as risk-sharing mechanisms, not simplification tools. What strikes me is how this evolution is forcing industry to rethink HEOR infrastructure. We're seeing more integrated evidence generation teams spanning R&D, commercial, and market access.

SaraRight, and from the payer side, we're simultaneously seeing pushback against overly optimistic HEOR models. The evidence demands are becoming more methodologically rigorous — particularly around extrapolation and handling of missing data in rare diseases. That's where the third topic intersects: value demonstration for complex therapies.

MarcusAbsolutely. Complex therapies like cell and gene therapies are pushing HTA methodologies to their limits. Payers are demanding more nuanced approaches beyond traditional cost-per-QALY calculations. We're seeing increased focus on multi-criteria decision analysis and willingness-to-pay thresholds that account for disease severity and unmet need.

SaraWhat's striking here is how payer expectations are diverging across regions. In Europe, HTA bodies are increasingly accepting surrogate endpoints when validated, while US payers remain skeptical. The budget impact question there is one the field hasn't fully worked out yet — especially for ultra-orphan indications with small populations.

MarcusThat's exactly right. And it connects to our final topic: rare disease HTA methodological shifts. We're seeing more adaptive licensing frameworks and real-world data requirements for post-approval monitoring. The challenge is generating meaningful evidence in populations with limited data.

SaraThe part that gives me pause is the sustainability aspect. Payers are asking for longer-term evidence generation commitments, which creates tension with commercial timelines. I keep coming back to how HEOR teams need to design studies that serve both access and commercial objectives.

MarcusThis is one of those stories where the tension is productive. It's forcing more creative approaches to evidence generation. Honestly, this caught me off guard — how quickly payer expectations have evolved beyond traditional clinical trial data.

SaraSame here. The operational reality is that HEOR teams need to become more agile. The evidence demands aren't static; they're evolving as real-world data accumulates. That's why we're seeing more emphasis on living evidence frameworks.

MarcusExactly. Let's move to our next topic: real-world evidence integration challenges.

MarcusReal-world evidence integration is facing significant hurdles despite its growing importance. The primary challenge is data quality and standardization. Payers are increasingly requiring RWE that meets the same methodological rigor as randomized controlled trials, but the data sources often lack that consistency.

SaraThat's one read — I'd frame it slightly differently. The real bottleneck is regulatory acceptance. HTA bodies are still skeptical of RWE for initial reimbursement decisions, particularly for innovative therapies. The evidence demands are there, but the pathway for submission remains unclear. What strikes me is how this creates a catch-22: payers want real-world data but won't use it for coverage decisions.

MarcusThat connects to something I keep coming back to — the infrastructure gap. Many companies lack the federated data networks needed to generate robust RWE. The part that gives me pause is how this affects development planning. If RWE requirements are moving to Phase II, companies need to design studies with embedded RWE collection from the start.

SaraThe part that gives me pause is the cost. Generating high-quality RWE is resource-intensive, especially for rare diseases. Payers are demanding more evidence without acknowledging the operational burden. I wonder if that's the full picture though — we're also seeing more public-private partnerships for data sharing, which could alleviate some challenges.

MarcusThat's fair, though I think payers would see it differently. They view data sharing as a responsibility of manufacturers, not an opportunity. What strikes me is how this evolution is forcing industry to rethink HEOR infrastructure. We're seeing more integrated evidence generation teams spanning R&D, commercial, and market access.

SaraRight, and from the payer side, we're simultaneously seeing pushback against overly optimistic RWE submissions. The evidence demands are becoming more methodologically rigorous — particularly around confounding control and external validity. That's where the third topic intersects: value demonstration for complex therapies.

MarcusAbsolutely. Complex therapies are pushing HTA methodologies to their limits. Payers are demanding more nuanced approaches beyond traditional cost-per-QALY calculations. We're seeing increased focus on multi-criteria decision analysis and willingness-to-pay thresholds that account for disease severity and unmet need.

SaraWhat's striking here is how payer expectations are diverging across regions. In Europe, HTA bodies are increasingly accepting surrogate endpoints when validated, while US payers remain skeptical. The budget impact question there is one the field hasn't fully worked out yet — especially for ultra-orphan indications with small populations.

MarcusThat's exactly right. And it connects to our final topic: rare disease HTA methodological shifts. We're seeing more adaptive licensing frameworks and real-world data requirements for post-approval monitoring. The challenge is generating meaningful evidence in populations with limited data.

SaraThe part that gives me pause is the sustainability aspect. Payers are asking for longer-term evidence generation commitments, which creates tension with commercial timelines. I keep coming back to how HEOR teams need to design studies that serve both access and commercial objectives.

MarcusThis is one of those stories where the tension is productive. It's forcing more creative approaches to evidence generation. Honestly, this caught me off guard — how quickly payer expectations have evolved beyond traditional clinical trial data.

SaraSame here. The operational reality is that HEOR teams need to become more agile. The evidence demands aren't static; they're evolving as real-world data accumulates. That's why we're seeing more emphasis on living evidence frameworks.

MarcusExactly. Let's move to value demonstration for complex therapies.

MarcusValue demonstration for complex therapies is becoming increasingly challenging. These therapies often have high upfront costs with uncertain long-term benefits. Payers are demanding more sophisticated economic models that capture both clinical and economic impacts across the care continuum.

SaraThat's one read — I'd frame it slightly differently. The real challenge is aligning value definitions. Payers want cost-effectiveness, manufacturers want commercial viability, and patients want access. The evidence demands are forcing us to find common ground through value-based agreements. What strikes me is how this creates tension for first-in-class therapies where reference products don't exist.

MarcusThat connects to something I keep coming back to — the budget impact considerations. Payers are increasingly requiring transparent modeling of opportunity costs. It's not just about the drug's price but about displacing other services. The part that gives me pause is how this affects development timelines for breakthrough therapies.

SaraThe part that gives me pause is the operational burden. HEOR teams are now expected to generate robust evidence while maintaining commercial viability. That's a delicate balance. I wonder if that's the full picture though — we're also seeing payers experiment with value-based contracts, which could actually streamline evidence requirements if designed well.

MarcusThat's fair, though I think payers would see it differently. They view value-based contracts as risk-sharing mechanisms, not simplification tools. What strikes me is how this evolution is forcing industry to rethink HEOR infrastructure. We're seeing more integrated evidence generation teams spanning R&D, commercial, and market access.

SaraRight, and from the payer side, we're simultaneously seeing pushback against overly optimistic HEOR models. The evidence demands are becoming more methodologically rigorous — particularly around extrapolation and handling of missing data in rare diseases. That's where our final topic intersects: rare disease HTA methodological shifts.

MarcusAbsolutely. Rare diseases are pushing HTA methodologies to their limits. Payers are demanding more nuanced approaches beyond traditional cost-per-QALY calculations. We're seeing increased focus on multi-criteria decision analysis and willingness-to-pay thresholds that account for disease severity and unmet need.

SaraWhat's striking here is how payer expectations are diverging across regions. In Europe, HTA bodies are increasingly accepting surrogate endpoints when validated, while US payers remain skeptical. The budget impact question there is one the field hasn't fully worked out yet — especially for ultra-orphan indications with small populations.

MarcusThat's exactly right. And it connects to our earlier discussion on real-world evidence. The challenge is generating meaningful evidence in populations with limited data. Payers are demanding more evidence while acknowledging the ethical constraints of placebo controls.

SaraThe part that gives me pause is the sustainability aspect. Payers are asking for longer-term evidence generation commitments, which creates tension with commercial timelines. I keep coming back to how HEOR teams need to design studies that serve both access and commercial objectives.

MarcusThis is one of those stories where the tension is productive. It's forcing more creative approaches to evidence generation. Honestly, this caught me off guard — how quickly payer expectations have evolved beyond traditional clinical trial data.

SaraSame here. The operational reality is that HEOR teams need to become more agile. The evidence demands aren't static; they're evolving as real-world data accumulates. That's why we're seeing more emphasis on living evidence frameworks.

MarcusExactly. Let's conclude with rare disease HTA methodological shifts.

MarcusRare disease HTA methodological shifts are accelerating. We're seeing more acceptance of natural history studies as comparators and increased use of real-world evidence for post-approval monitoring. Payers are demanding more flexible approaches to address the unique challenges of rare disease development.

SaraThat's one read — I'd frame it slightly differently. The real evolution is in how payers are defining value. For rare diseases, traditional cost-effectiveness thresholds are being replaced by willingness-to-pay assessments that consider disease severity and unmet need. The evidence demands are forcing us to rethink value frameworks. What strikes me is how this creates opportunities for innovative reimbursement models.

MarcusThat connects to something I keep coming back to — the budget impact considerations. Payers are increasingly requiring transparent modeling of opportunity costs. It's not just about the drug's price but about displacing other services. The part that gives me pause is how this affects development timelines for breakthrough therapies.

SaraThe part that gives me pause is the operational burden. HEOR teams are now expected to generate robust evidence while maintaining commercial viability. That's a delicate balance. I wonder if that's the full picture though — we're also seeing payers experiment with value-based contracts, which could actually streamline evidence requirements if designed well.

MarcusThat's fair, though I think payers would see it differently. They view value-based contracts as risk-sharing mechanisms, not simplification tools. What strikes me is how this evolution is forcing industry to rethink HEOR infrastructure. We're seeing more integrated evidence generation teams spanning R&D, commercial, and market access.

SaraRight, and from the payer side, we're simultaneously seeing pushback against overly optimistic HEOR models. The evidence demands are becoming more methodologically rigorous — particularly around extrapolation and handling of missing data. That's where our first topic intersects: payer evidence requirements evolution.

MarcusAbsolutely. The evidence demands are reshaping entire HEOR strategies. Payers are demanding earlier evidence generation, often during Phase II, to inform coverage decisions. This requires HEOR teams to embed economic models and patient-reported outcomes much earlier in development.

SaraWhat's striking here is how payer expectations are diverging across regions. In Europe, HTA bodies are increasingly accepting surrogate endpoints when validated, while US payers remain skeptical. The budget impact question there is one the field hasn't fully worked out yet — especially for ultra-orphan indications with small populations.

MarcusThat's exactly right. And it connects to our discussion on real-world evidence integration. The challenge is generating meaningful evidence in populations with limited data. Payers are demanding more evidence while acknowledging the ethical constraints of placebo controls.

SaraThe part that gives me pause is the sustainability aspect. Payers are asking for longer-term evidence generation commitments, which creates tension with commercial timelines. I keep coming back to how HEOR teams need to design studies that serve both access and commercial objectives.

MarcusThis is one of those stories where the tension is productive. It's forcing more creative approaches to evidence generation. Honestly, this caught me off guard — how quickly payer expectations have evolved beyond traditional clinical trial data.

SaraSame here. The operational reality is that HEOR teams need to become more agile. The evidence demands aren't static; they're evolving as real-world data accumulates. That's why we're seeing more emphasis on living evidence frameworks.

SaraA lot to think about today. I'll be watching how payer evidence demands continue to reshape HEOR infrastructure, particularly the move toward earlier evidence generation and value-based agreements.

MarcusSame — and for me the thread running through today is the tension between payer demands for robust evidence and the operational realities of drug development. That balance will define market access success in the coming years.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.